

# Prevention of POstoperative Nausea and Vomiting with metoclopramide and dexamethasone

<b>Submission date</b> 07/09/2005	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 17/10/2005	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 19/02/2008	<b>Condition category</b> Signs and Symptoms	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Prof Derk Olthoff

### Contact details

Liebigstr. 20  
Leipzig  
Germany  
D-04103  
+49 (0)341 9717701  
olthoff@medizin.uni-leipzig.de

## Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N/A

# Study information

## Scientific Title

## Acronym

MultiPONV

## Study objectives

A prophylactic treatment of postoperative nausea and vomiting consisting of an optimal dosage of metoclopramide combined with dexamethasone increases effectiveness and lowers side effects.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Not provided at time of registration

## Study design

Randomised controlled trial

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Hospital

## Study type(s)

Prevention

## Participant information sheet

## Health condition(s) or problem(s) studied

Postoperative nausea and/or vomiting following inhalational or regional anaesthesia.

## Interventions

The patients were randomised to receive either of 0, 10, 25 or 50 mg metoclopramide in addition to 8 mg dexamethasone.

## Intervention Type

Drug

## Phase

Not Specified

## Drug/device/biological/vaccine name(s)

Metoclopramide, dexamethasone

### **Primary outcome measure**

Occurrence of nausea and/or vomiting within 24 hours after the end of surgery.

### **Secondary outcome measures**

1. Occurrence of post-operative nausea (PON) and vomiting (POV) separately
2. Frequency and severity of PON and POV
3. Time to first PONV event
4. Need of rescue medication
5. Frequency of hypotension and arrhythmia after intra-operative administration of the study drugs
6. Frequency and severity of adverse effects within 24 hours after the end of surgery:
  - 6.1. Headache
  - 6.2. Dizziness
  - 6.3. Drowsiness
  - 6.4. Dry mouth
  - 6.5. Itching
  - 6.6. Flush
  - 6.7. Urticaria
  - 6.8. Restlessness
  - 6.9. Extrapyrarnidal symptoms
  - 6.10. Dyskinesia
  - 6.11. Central-anticholinergic syndrome
  - 6.12. Bradycardia/tachycardia

### **Overall study start date**

12/01/2004

### **Completion date**

14/12/2004

## **Eligibility**

### **Key inclusion criteria**

1. Age greater than 18 years
2. Patient receives balanced anaesthesia (with intubation) or spinal, peridural, or combined spinal epidural anaesthesia for any of the following surgeries:
  - 2.1. Hysterectomy
  - 2.2. Cholecystectomy
  - 2.3. Hernia repair
  - 2.4. Otorhinolaryngological surgery
  - 2.5. Thyroid surgery
  - 2.6. Total endoprosthesis of the hip or knee
  - 2.7. Arthroscopy
3. Patient is able to answer questions regarding symptoms (taking his/her physical, emotional and mental constitution, understanding and compliance into consideration)
4. Informed consent in writing

### **Participant type(s)**

Patient

**Age group**

Adult

**Lower age limit**

18 Years

**Sex**

Both

**Target number of participants**

3000

**Key exclusion criteria**

1. Anaesthesiological risk level of American Society of Anaesthesiologists (ASA) IV
2. Presence of at least one of the following cardiac risk factors:
  - 2.1. Unstable angina pectoris
  - 2.2. Heart failure with New York Heart Association (NYHA) greater than or equal to III and/or left ventricular ejection fraction (LVEF) less than 40%
  - 2.3. Atrioventricular block grade II or III
3. Current treatment with any of the following:
  - 3.1. Study medication
  - 3.2. Other anti-emetic drugs except ranitidine
  - 3.3. Selective serotonin reuptake inhibitors (SSRIs)
  - 3.4. Monoamine oxidase (MAO) inhibitors
  - 3.5. Tricyclic antidepressants
  - 3.6. Antiarrhythmics class I or III
4. Disposition of the patient to malignant hyperthermia, or known occurrence thereof
5. History of any of the following diseases:
  - 5.1. Parkinson's disease and other extrapyramidal-motoric impairment
  - 5.2. Hepatic insufficiency (alanine aminotransferase [ALT] and/or aspartate aminotransferase [AST] greater than 2 x upper normal value [UNV])
  - 5.3. Renal insufficiency (Creatinine greater than 2 x UNV)
  - 5.4. Pheochromocytoma
  - 5.5. Mechanical ileus
  - 5.6. Epilepsy
6. Known anaphylaxis following any of the study drugs
7. Pregnancy or breast feeding
8. Participation in another therapeutic trial
9. Planned or foreseeable post-operative application of propofol
10. Planned or foreseeable post-operative artificial respiration
11. Planned or foreseeable leaving of a stomach tube post-operatively

**Date of first enrolment**

12/01/2004

**Date of final enrolment**

14/12/2004

**Locations**

**Countries of recruitment**

Germany

**Study participating centre**

Liebigstr. 20

Leipzig

Germany

D-04103

## **Sponsor information**

**Organisation**

University of Leipzig (Germany)

**Sponsor details**

Ritterstr. 26

Leipzig

Germany

D-04109

+49 (0)341 9730100

kanzler@uni-leipzig.de

**Sponsor type**

University/education

**ROR**

<https://ror.org/03s7gtk40>

## **Funder(s)**

**Funder type**

University/education

**Funder Name**

Self-funded by the Department of Anaesthesiology and Intensive Care Medicine and by the Committee of Clinical Innovation of the University of Leipzig (Germany).

**Funder Name**

Supply of the study drugs free of charge by the manufacturers.

# Results and Publications

**Publication and dissemination plan**  
Not provided at time of registration

**Intention to publish date**

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**  
Not provided at time of registration

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	Results	12/08/2006		Yes	No